ImStem Biotechnology today announces the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
The core technology of ImStem Biotechnology Inc. has recently been granted the patent authorization of the national patent office of Japan and Australia.
The FDA has lifted the clinical hold and cleared the Investigational New Drug (IND) application to evaluate IMS001 for the treatment of multiple sclerosis (MS).
Emerging preclinical and clinical literature support MSCs may be appropriate to develop for COVID-19 as well as non-COVID-19 ARDS. ImStem’s investigational MSC candidate IMS001 is to be considered for further development in COVID19 and ARDS from other causes.
UConn TIP company ImSTEM Biotechnology is conducting a clinical trial to test their experimental human embryonic stem cell-derived mesenchymal stem cell therapy for the treatment of multiple sclerosis.